Between April 2023 and March 2024, Humira accounted for top medication spend for Vizient pharmacy program participants, according to a Vizient report published July 30.
To assess medication expenditure in health systems, Vizient collected data from hospital, non-acute and pediatric care clients for its Pharmacy Market Outlook report. Medications from outsourced compounding pharmacies and 340B purchases were not included.
Here are the No. 1 medications by cost and utilization across eight service lines and therapeutic areas:
Autoimmune and inflammatory diseases: Humira (adalimumab), a medication for rheumatoid arthritis, Crohn's disease and other conditions
Cardiopulmonary diseases: Trikafta (elexacaftor/tezacaftor/ivacaftor), a cystic fibrosis drug
Endocrine and metabolic diseases: Ozempic (semaglutide), a Type 2 diabetes therapy
Hematological: Eliquis (apixaban), a medicine to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Infectious diseases: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), an HIV-1 infection treatment
Neurology: Ocrevus (ocrelizumab), a multiple sclerosis medication
Oncology: Keytruda (pembrolizumab), a drug approved for more than a dozen cancers
Plasma: Albumin blood test, which helps evaluate for kidney disease and liver disease